AU644148B2 - Treatment of cataract with 15-keto-prostaglandin compounds - Google Patents

Treatment of cataract with 15-keto-prostaglandin compounds Download PDF

Info

Publication number
AU644148B2
AU644148B2 AU74047/91A AU7404791A AU644148B2 AU 644148 B2 AU644148 B2 AU 644148B2 AU 74047/91 A AU74047/91 A AU 74047/91A AU 7404791 A AU7404791 A AU 7404791A AU 644148 B2 AU644148 B2 AU 644148B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
substituted
unsubstituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU74047/91A
Other languages
English (en)
Other versions
AU7404791A (en
Inventor
Ruyji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of AU7404791A publication Critical patent/AU7404791A/en
Assigned to R-TECH UENO, LTD. reassignment R-TECH UENO, LTD. Alteration of Name(s) of Applicant(s) under S113 Assignors: KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO
Application granted granted Critical
Publication of AU644148B2 publication Critical patent/AU644148B2/en
Assigned to SUCAMPO AG reassignment SUCAMPO AG Alteration of Name(s) in Register under S187 Assignors: R-TECH UENO, LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU74047/91A 1990-04-04 1991-04-03 Treatment of cataract with 15-keto-prostaglandin compounds Expired AU644148B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2-90895 1990-04-04
JP9089590 1990-04-04
JP22164690 1990-08-22
JP2-221646 1990-08-22
JP3-29310 1991-01-29
JP2931091 1991-01-29

Publications (2)

Publication Number Publication Date
AU7404791A AU7404791A (en) 1991-10-10
AU644148B2 true AU644148B2 (en) 1993-12-02

Family

ID=27286510

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74047/91A Expired AU644148B2 (en) 1990-04-04 1991-04-03 Treatment of cataract with 15-keto-prostaglandin compounds

Country Status (11)

Country Link
US (2) US5212324A (en:Method)
EP (1) EP0453127B1 (en:Method)
KR (1) KR970005172B1 (en:Method)
AT (1) ATE169219T1 (en:Method)
AU (1) AU644148B2 (en:Method)
CA (1) CA2039420C (en:Method)
DE (1) DE69129921T2 (en:Method)
DK (1) DK0453127T3 (en:Method)
ES (1) ES2119762T3 (en:Method)
GR (1) GR3027666T3 (en:Method)
TW (2) TW249226B (en:Method)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (en:Method) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
EP0735895B1 (en) * 1993-11-19 2006-01-18 The University Of Sydney A method for preventing or controlling cataract
SE9403160D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
WO1997047595A1 (fr) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Antagoniste de l'endotheline
WO1999012898A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
AU731153B2 (en) * 1997-09-09 2001-03-22 Duke University Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
AU739343B2 (en) * 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
CN100506232C (zh) * 2000-03-16 2009-07-01 苏坎波公司 用于治疗眼压过高和青光眼的组合物
DE60138371D1 (de) 2000-03-24 2009-05-28 Sucampo Ag PROSTAGLANDINE zur Behandlung von Lichtstrahlung erzeugten Augenerkrankungen wie Photoretinitis
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
NZ521784A (en) * 2000-04-06 2005-04-29 Sucampo Ag Bile secretion promoting composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
MXPA04001604A (es) * 2001-08-23 2004-07-08 Sucampo Ag Metodo y composicion para tratamiento de hipertension ocular y glaucoma.
NZ531503A (en) 2001-08-31 2006-01-27 Sucampo Ag Prostaglandin analogs as chloride channel opener
US8580851B2 (en) * 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
CA2502439C (en) * 2002-10-23 2011-11-22 Sucampo Ag Prostaglandin compounds for the treatment of obesity
MXPA05006981A (es) 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
KR101118935B1 (ko) 2003-08-21 2012-03-13 가부시키가이샤 아루떼꾸 우에노 안과용 조성물
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7321057B2 (en) * 2004-08-02 2008-01-22 R-Tech Ueno, Ltd. Method for manufacturing prostaglandin analogue
WO2006080549A2 (en) 2005-01-27 2006-08-03 Sucampo Ag Method and composition for treating central nervous system disorders
EP2308495A1 (en) 2005-03-04 2011-04-13 Sucampo AG Method and composition for treating peripheral vascular diseases
US9241918B2 (en) 2005-03-16 2016-01-26 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
PT1871380E (pt) * 2005-04-12 2011-11-21 Sucampo Ag Utilização combinada de composto de prostaglandina e inibidor de bomba de protões para o tratamento de distúrbios gastrointestinais
KR101465269B1 (ko) 2006-01-24 2014-11-26 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
AU2007208632B2 (en) 2006-01-24 2012-01-19 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
KR20140035363A (ko) 2011-04-07 2014-03-21 수캄포 아게 안정피로 치료 방법
MX359697B (es) 2011-08-05 2018-10-08 Sucampo Ag Metodo para tratar esquizofrenia.
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
AR105029A1 (es) 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
AU625718B2 (en) * 1988-05-11 1992-07-16 Sucampo Ag Tracheobronchodilator

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
EP0455264B1 (en) * 1987-09-18 1994-07-13 R-Tech Ueno Ltd. Ocular hypotensive agents
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
DE68906193T2 (de) * 1988-05-23 1993-08-05 Ueno Seiyaku Oyo Kenkyujo Kk Hypersphyxia verursachende zusammensetzung.
ATE162074T1 (de) * 1988-10-01 1998-01-15 R Tech Ueno Ltd Oculare hypotensive mittel
TW205508B (en:Method) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625718B2 (en) * 1988-05-11 1992-07-16 Sucampo Ag Tracheobronchodilator
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series

Also Published As

Publication number Publication date
US5212324A (en) 1993-05-18
CA2039420A1 (en) 1991-10-05
CA2039420C (en) 1996-12-10
ES2119762T3 (es) 1998-10-16
DK0453127T3 (da) 1998-10-26
EP0453127B1 (en) 1998-08-05
GR3027666T3 (en) 1998-11-30
DE69129921D1 (de) 1998-09-10
US5686487A (en) 1997-11-11
EP0453127A2 (en) 1991-10-23
DE69129921T2 (de) 1999-01-14
ATE169219T1 (de) 1998-08-15
TW249226B (en:Method) 1995-06-11
AU7404791A (en) 1991-10-10
KR910018027A (ko) 1991-11-30
KR970005172B1 (ko) 1997-04-14
TW224942B (en:Method) 1994-06-11
EP0453127A3 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
AU644148B2 (en) Treatment of cataract with 15-keto-prostaglandin compounds
US5432174A (en) Treatment of ocular hypertension
US5426115A (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5252605A (en) Promotion of wound-healing with 15-keto-prostaglandin compounds
US5164415A (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
US5346921A (en) Treatment of inflammation with 15-keto-prostaglandin compounds
EP0342003B1 (en) Use of 15-ketoprostaglandin e or f compounds for uterine contraction
KR0127297B1 (ko) 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료
KR960010435B1 (ko) 상승병용을 이용한 안고혈압 치료
EP0430551B1 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
EP0469782B1 (en) Treatment of cataract with prostacyclin compounds
US5185374A (en) Use of 15-ketoprostaglandin E or F compounds for uterine contraction